Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor

Journal of Immunology

Volumn 170, Issue 6, 2003, Pages 3162-3170

  Lu, You ^a   Wei, Yu quan ^a   Tian, Ling ^a   Zhao, Xia ^b   Yang, Li ^a   Hu, Bin ^a   Kan, Bin ^a   Wen, Yan jun ^a   Liu, Feng ^a   Deng, Hong xin ^a   Li, Jiong ^a   Mao, Yong qiu ^a   Lei, Song ^a   Huang, Mei juan ^a   Peng, Feng ^a   Jiang, Yu ^a   Zhou, Hao ^a   Zhou, Li qun ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN SUBCLASS; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PLASMID DNA;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; BIOACCUMULATION; BLOOD LEVEL; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL ISOLATION; CELL KILLING; CELL LEVEL; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; FLOW CYTOMETRY; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR CELL; WESTERN BLOTTING;

EID: 0037443418     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.6.3162     Document Type: Article

References (59)

1. Downward, J., Y. Yarden, E. Mayes, G. Scrace, N. Totty, P. Stockwell, A. Ullrich, J. Schlessinger, and M. D. Waterfield. 1984. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521.
2. Yamamoto, T., T. Nishida, N. Miyajima, S. Kawai, T. Ooi, and K. Toyoshima. 1983. The erbB gene of avian erythroblastosis virus is a member of the src gene family. Cell 35:71.
3. Ullrich A., and J. Schlessinger. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203.
4. Velu, T. J., L. Beguinot, W. C. Vass, M. C. Willingham, G. T. Merlino, I. Pastan, and D. R. Lowy. 1987. Epidermal growth factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238:1408.
5. Di Fiore, P. P., J. H. Pierce, T. P. Fleming, R. Hazan, A. Ullrich, C. R. King, J. Schlessinger, and S. A. Aaronson. 1987. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51:1063.
6. Gleave, M. E., J. T. Hsieh, H. C. Wu, S. J. Hong, H. E. Zhau, P. D. Guthrie, and L. W. Chung. 1993. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res. 53:5300.
7. Berger, M. S., W. J. Gullick, C. Greenfield, S. Evans, B. J. Addis, and M. D. Waterfield. 1987. Epidermal growth factor receptors in lung tumors. J. Pathol. 152:297.
8. Veale, D., T. Asbcoft, C. Marsh, G. J. Gibson, and A. L. Harris. 1987. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer 55:513.
9. Veale, D., N. Kerr, G. J. Gibson, and A. L. Harris. 1989. Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res. 49:1313.
10. Sainsbury, J. R., J. R. Farndon, G. V. Sherbet, and A. L. Harris. 1985. Epidermalgrowth-factor receptors and estrogen receptors in human breast cancer. Lancet 1:364.
11. Neal, D. E., C. Marsh, M. K. Bennett, P. D. Abel, R. R. Hall, J. R. C. Sainsbury, and A. L. Harris. 1985. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet 1:366.
12. Neal, D. E., L. Sharples, K. Smith, J. A. Fennelly, R. R. Hall, and A. L. Harris. 1990. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619.
13. Wong, A. J., S. H. Bigner, D. D. Bigner, K. W. Kinzler, S. R. Hamilton, and B. Vogelstein. 1987. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. USA 84:6899.
14. Mendelsohn, J. 2000. Blockade of receptors for growth factors: An anticancer therapy: Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 6:747.
15. Medelson, J., D. M. Shin, N. Donato, F. Khuri, R. Radinsky, B. S. Glisson, H. J. Shin, E. Metz, D. Pfister, R. Perez-Soler, et al. 1999. A phase I study of chimerized antiepidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC). Proc. Am. Soc. Clin. Oncol. 18:389.a.
16. Krieg, A. M., T. Wu, R. Weeratna, S. M. Efler, L. L. Homan, L. Yang, A.-K. Yi, D. Short, and H. L. Davis. 1998. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA 95:12631.
17. Wei, Y.-Q., M.-J. Huang, L. Yang, X. Zhao, L. Tian, Y. Lu, J.-M. Shu, C.-J. Lu, T. Niu, and K. Kang. 2001. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factors as a model antigen. Proc. Natl. Acad. Sci. USA 98:11545.
18. Wei, Y.-Q., Q-R. Wang, X. Zhao, L. Yang, L. Tian, Y. Lu, B. Kang, C.-J. Lu, M.-J. Huang, Y.-Y. Lou, et al. 2000. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. 6:1160.
19. Zheng, F., G. C. Kundu, Z. J. Zhang, J. Ward. F. DeMayo, and A. B. Mukherjee. 1999. Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. Nat. Med. 5:1018.
20. Wei, Y.-Q., X. Zhao, Y. Kariya, H. Fukata, K. Teshigawara, and A. Uchida. 1996. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of γδ cells and heat shock protein 70. Cancer Res. 56:1104.
21. Miljan, E. A., E. J. Meuillet, B. Mania-Farnell, D. George, H. Yamamoto, H.-G. Simon, and E. G. Bremer. 2002. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J. Biol. Chem. 277:10108.
22. Mascker, H. T., M. S. Do, and S. Levy. 1998. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc. Natl. Acad. Sci. USA 95:2458.
23. Fields, R. C., K. Shimizu, and J. J. Mule. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:9482.
24. - cells in the production of IL-4, IL-10, and IFN-γ and in Trypanosome-elicited immunosuppression. J. Immunol. 161:6189.
25. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211.
26. Horton, H. M., D. Anderson, P. Hernandez, K. M. Barnhart, J. A. Norman, and S. E. Parker. 1999. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α. Proc. Natl. Acad. Sci. USA 96:1553.
27. Sauter, B. V., O. Martinet, W. J. Zhang, J. Mandeli, and S. L. C. Woo. 2000. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA 97:4802.
28. Kaplan, E. L., and P. Meier. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:475.
29. Peto, R., and J. Peto. 1972. Asymptotically efficient rank invariant test procedures. J. R. Stat. Soc. 135:185.
30. Bianchi, R., U. Grohmann, M. L. Belladonna, S. Silla, F. Fallarino, E. Ayroldi, M. C. Fioretti, and P. Puccetti. 1996. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol. 157:1589.
31. Romagnani, S. 1997. The Th1/Th2 paradigm. Immunol. Today 18:263.
32. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.
33. Carbone, F. R., C. Kurts, S. R. Bennett, J. F. Miller, and W. R. Heath. 1998. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today 19:368.
34. + T cells in the priming and effector/memory phases of adoptive immunotherapy J. Immunol. 165:4246.
35. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.
36. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
37. + T cell help. J. Exp. Med. 186:65.
38. Toes, R. E., F. Ossendorp, R. Offringa, and C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189:753.
39. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
40. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161:5500.
41. Houghton, A. N., J. S. Gold, and N. E. Blachere. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13:134.
42. Pardoll, D. M. 1999. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96:5340.
43. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96:2982.
44. Naftzger, C., Y. Takechi, H. Kohda, I. Ham, S. Vijayasaradhi, and A. N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA 93:14809.
45. Ohashi, P. S. 1996. T cell selection and autoimmunity: flexibility and tuning. Curr. Opin. Immunol. 8:808.
46. + T cells, are required for the development of experimental autoimmune gastritis. Immunology 93:405.
47. Kumar, V., K. Stellrecht, and Sercarz, E. 1996. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J. Exp. Med. 184:1609.
48. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
49. + suppressor T-cells. Cancer Res. 1989 49:1649.
50. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795.
51. Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J. L. Taupin, E. Vivier, P. Anderson, and R. Kiessling. 1993. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53:5610.
52. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
53. Ye, X., J. McCarrick, L. Jewett, and B. B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91:3916
54. Ochsenbein A. F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96:2233.
55. Stoscheck, C. M., and G. Carpenter. 1984. Down regulation of epidermal growth factor receptor: direct demonstration of receptor degradation in human fibroblasts. J. Cell Biol. 98:1048.
56. Wiley, H. S. 1988. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J. Cell Biol. 107:801.
57. French, A. R., G. P. Sudlow, H. S. Wiley, and D. A. Lauffenburger. 1994. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. J. Biol. Chem. 269:15749.
58. Kurten, R. C., D. L. Cadena, and G. N. Gill. 1996. Enhanced degradation of EGF receptors by assorting nexin, SNX1. Science 272:1008.
59. Rubin, G. J., A. Chakraborty, M. F. Melhem, Q. Zeng, and D. J. Tweardy. 1997. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 15:409.